Avacta Group plc: Avacta Announces AffiDx SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer and pre|CISION platforms is pleased

Related Keywords

South Africa ,United Kingdom ,Madrid ,Spain ,Alastair Smith ,Lily Jeffery ,Avacta Group ,Zyme Communications ,World Health Organisation ,Chief Executive ,Regional Media ,Avacta ,Group ,Nnounces ,Ffidx ,Cars ,Ntigen ,Bilateral ,Low ,Pest ,Detects ,Micron ,Variant ,